Annexon closes $100M round!

July 24, 2020

Mike Rose, CEO

Annexon Biosciences just closed a $100 million funding round to advance their pipeline of classical complement therapeutics. Annexon is a clinical-stage biopharmaceutical company developing novel therapies for patients with disorders of the body, brain and eye.

We’ve been working with Annexon since 2016, when they were in the pre-clinical stage. Before Annexon hired a CFO, we provided high-level finance consulting along with budgeting and forecasting, equity admin and payroll services. More recently, we’ve helped the internal accounting team set up contract tracking, prepare for audits and file SEC reports.